- Ticagrelor Uses, Side Effects Warnings - Drugs. com
Ticagrelor is used to lower your risk of heart attack, stroke, or death due to a blocked artery or a prior heart attack Ticagrelor is also used to lower your risk of blood clots if you have coronary artery disease (decreased blood flow to the heart) and have been treated with stents to open clogged arteries
- Ticagrelor - Wikipedia
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries
- Ticagrelor (oral route) - Mayo Clinic
Ticagrelor is used alone or together with aspirin to lessen the chance of heart attack or stroke in patients with acute coronary syndrome (ACS) or a history of heart attack Acute coronary syndrome is a condition where the blood flow to the heart is blocked
- Ticagrelor: Side Effects, Dosage, Uses, and More - Healthline
Ticagrelor is used to improve heart health in people who have had a heart attack, or who have a condition called acute coronary syndrome (ACS) With this condition, your heart doesn’t receive
- Ticagrelor (Brilinta®): Uses Side Effects - Cleveland Clinic
TICAGRELOR (TYE ka GREL or) helps to prevent blood clots It lowers the risk of heart attacks or stroke in people with coronary artery disease (such as chest pain or heart attack) or a previous stroke or mini-stroke It is in a class of drugs called anti-platelets
- Brilinta (ticagrelor) - Uses, Side Effects, and More
Find patient medical information for Brilinta (ticagrelor) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Ticagrelor: Side Effects, Uses, Dosage, Interactions, Warnings
Ticagrelor is a prescription medication used to treat Acute Coronary Syndrome or History of Myocardial Infarction (MI), Coronary Artery Disease, Acute Ischemic Stroke, or Transient Ischemic Attack (TIA)
- TICAGRELOR tablet, film coated - DailyMed
Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI For at least the first 12 months following ACS, it is superior to clopidogrel
|